

Denise Perry Simmons
2300 Olympia Drive #270464
Flower Mound, TX 75028
214.399.0014(c)
doccancer51@gmail.com

EDUCATION and TRAINING

Cancer Research Fellow, NIH-National Cancer Institute, Bethesda, MD 2000-2005

Medicinal Chemistry Fellow, University of Texas College of Pharmacy, Austin, TX 1998

Ph.D. Biological Sciences 3.78 GPA The University of Texas, Austin and UTMD Anderson Dissertation title: "The Role of Interleukin-1 Receptors in Tumor Promoter-elicited Events in Skin Carcinogenesis. 1998

B. A. Biology, Chemistry minor, electives: business law, contract law, tort law, The University of Texas, Austin, TX.1976

AREAS of DEMONSTRATED COMPETENCY and HIGH PROFICIENCY:

*Leadership, community relations, consulting, executive, strategic planning – vision, mission, senior management :boards, healthcare, academia – domestic/international, biotech, government- federal/state/city, industry, biomedical – domestic, international, centers, startups, grant consortia

*Fiscal responsibility: Banking – commercial, consumer and bank daily balance – multimillion dollar, Cost Centers – budget oversight and fund acquisition, Contract Negotiations – budget development, oversight - multimillion dollar, seed funding; Cost efficiency, Annual Reports.

*Policy, Procedure and Operations: FDA, GCP, GLP, GMP, HIPPA, IACUC, ICH, IDE, IND, IP, IRB, JCAHCO/TJC, P&L, SOP, Core Facilities, Cost Centers, Service Lines

*Teaching: Upper division immunology course design with accompanying lab; Research education and training program development and execution: high school through postdoctoral: summer internships, faculty sabbatical research experience; Faculty Career Development: senior administration partnerships and program design to develop faculty career growth senior level administrative intramural training; Graduate students and Faculty Seminars and One-on-One: Grant: writing, planning, managing, networking and marketing

*Therapeutic Areas: GI (surgical interventions GI tract digestive abnormalities), Neurology (vaccine), Oncology (14 specialties – clinical trials: protocol design through closeout, Phase I-IV), immunology & infectious Disease (diagnostics, screening, mechanism), Pharmacology (kinetics, dynamics)

*Models treatment and care development, mechanisms: *in silico* (patient safety, PCP-Referral System – transitions in care and patient navigation, patient satisfaction); *in vitro* (e.g. cells -primary and lines, 2Dcultures, peptide nucleic acid design, synthesis), *in vivo* (e.g. animal – jejunum-duodenum- bypass: canine, feline, o'possum), MNU-induced/ transgenic/xenografts, epithelial cancers/ skin carcinogenesis and inflammation), human subjects-clinical trials.

*Novel/Innovative discovery: devices, diagnostics, drug development (e.g. bio-informatics, breeding, confocal microscopy and dot assay, evidence-based, FACS, genomics, imaging, immuno-assays, mAb, pAb, genomics-blot/profile, mapping, libraries), proof of principle screen.

KEY INITIATIVE ACCOMPLISHMENTS (select)

Academia:

*2016: First Milestone National Research University Initiative – Carnegie Tier 1/115 Research Universities – data endpoint 2013-2014 (data start 2008) tenure as Sr. Director and Assistant VP Research University of North Texas (UNT)

*2014: First, Conference new Center NCI- The Center Strategic Scientific Initiatives: Translational Applications in STEM Symposium with UNT College of Engineering and UNT College of Business and UNT Health Science Ctr as UNT Assistant Vice President Research and Special Advisor to Vice President Research UNT Health Science Ctr

*2014: First National Endowment for the Humanities Regional Conference at UNT as UNT Assistant VP Research

*2014: First, UNT- Society for Advancement of Chicanos/Hispanics and Native Americans in Science (SACNAS) Conference Competitive Student Travel Awards as UNT Assistant VP Research

*2011: Texas Department of State Health Services (DSHS) and University of North Texas (UNT) MOU –DSHS first academic linkage; used as model; secondary data access, State collaboration and pipeline partnerships- as UNT Assistant VP Research

*2011: First seed funding MOU and academic- physician working group, UNT and Baylor Health Care System

*2009: SACNAS National Conference UNT sponsored. UNT President appointed head of strategic planning and execution University Research as Sr. Director UNT Research

*2003: Developed first upper division immunology course: course curriculum, lab design and pre- requisites BIOL 438, Cellular & Molecular Immunology University of Maryland System UMUC as NCI-Fellow and Adjunct Professor

Healthcare

*2015: Developed sustainable healthcare multidiscipline/-profession consortium to address advancing patient safety. Developed fundamental concept for Initial AHRQ grant submitted by consortium May 2016 uses *in silico* approaches to reduce healthcare costs and improve quality in PCP-referral system transitions of care.

*2012: First, Statewide Biomedical informatics Conference: CIOs (academic, medical technological) across state –Bio-informatics in Healthcare – Standardizing biospecimen banking for improving quality of secondary data: guest speakers Deputy Director USDHHS Office of the National Coordinator for Health Informatics Technology (ONC), NIH Director Bioinformatics, Texas Medical Association Vice President and Director Bioinformatics – as UNT Assistant VP Research.

*2008: Pfizer Corporate Partnership Patient Navigation Quality of Care and Patient Satisfaction John Theurer Cancer Ctr

*2007 Initiative Bio-specimen Banking Core Facility; developed infrastructure, lab design, instrumentation, initial specimen handling design, interim director, recruit and hire director, research assistant, applied and received grant funding facility

*2007 Phase IV clinical trial design – infrastructure and first PIV clinical trial John Theurer Cancer Ctr

*2007 Pharma Investigator Initiated Research Grants: internal process design, negotiations and subsequent award receipt – focus on cancer and co-morbidities

*2007: Medical Education: First, Research Nursing Clinical Oncology Research and Training program – Master and Certification, John Theurer Cancer Center as Director

*2006: Economics of improved patient care: Clinical Research Dollars, 120- fold revenue increase within first year; growth of clinical staff to 50+ and new pay-for-performance business models to support growth of Cancer Center as Director John Theurer Cancer Ctr

*2006: Economics of improved patient care in pay-for-performance: Operations Recovery of Expenses: developed and implemented strategy for recovery of expenses such that within first year recovered 88%, subsequent two-year period 98% as Director John Theurer Cancer Ctr

*2005: Visibility, Improved Quality, Growth of Cancer Center Initiative – website design, infrastructure design, development and funding to support through new model pharma contract negotiation, education and training grants, new proposal submission/process software, FDA and site initiation protocols

HONORS/AWARDS/ BOARDS (select)

2014 National Patient Advocacy Think Tank- Health Disparities Robert Wood Johnson
2013 College Business Logistics Chain, Supply Depart UNT Pre-doctoral Faculty Advisor
2012 Board: UNT McNair Advisory Board
2010 Editor, Dallas Regional Chamber, Life Science and Business Technology
2009 UNT President's Award Outstanding Achievements Research Development
2008 Outstanding Contributions as Director John Theurer Cancer Center
2008 Department Health Human Services National Center Minority Health & Health Disparities Committee Member
2006 Board Member IMPACT NJ: New Jersey Commission on Cancer Research
2004 NIH Outstanding Mentor Award
2003 NCI-Center for Cancer Research Federal Technology Transfer Award
2000 American Association Cancer Research Minority Scholar Cancer Research
2000 Cancer Research Training Award NCI re-awarded 2001, 2002, 2003, 2004
1998 NIH/NCI Postdoctoral Training Grant
1995 NCI Pre-doctoral Training Grant
1993 Kappa Omicron Nu Professional Honor Society
1993 NSF Pre-doctoral Fellowship, honorable mention biochemistry
1992 Governor Ann Richards Committee Higher Education Bill and policy analyses
1985 Kallestad Employee Achievement Award Research Innovation
1979 Benjamin Franklin Savings Number 1 rank student in Manager training class
1975 University Chicago Summer Internship Endocrinology Professor H. Guy Williams-Ashman

PROFESSIONAL EXPERIENCE

BLOCK 1: RESEARCH

2016- Present: Visiting Biomedical Research Faculty Department Chemistry University of North Texas
2000-2005: Cancer Research Training Award Fellow. National Cancer Institute. Bethesda, Maryland.
2003- 2005: Adjunct Assistant Professor Cellular & Molecular Immunology University of Maryland System University Maryland University College.
1998-2000: Medicinal Chemistry Fellow -NIH/NCI post-doctoral training grant. College of Pharmacy, University of Texas, Dept Medicinal Chemistry
1994-1998: Graduate Research Assistant III: *In vivo/in vitro* models in mechanisms carcinogenesis UT M.D. Anderson Science Park, Smithville, TX.
1988-1991: Research Associate Scientist Department Neurology. University of Texas Medical School, Texas Medical Center Houston.
1987-1988: Research Associate Rockefeller University NY. Research use of hybridoma technology for antibody production adhesion molecules Gerald Edelman, M.D., Ph.D.
1985-1987: Manager Core Tissue Culture and Experiment Facility _ Research Associate Scientist, Cellular and Molecular Biology, University of Chicago, Chicago, IL.
1981-1982: Research Associate Scientist Dept. Physiology – GI, University Texas Medical School, Texas Medical Center Houston
1980-1981: Assistant Manager, Ben Franklin Savings Fondren West, Houston, TX
1978-1980: Research Associate Scientist Dept. Cellular and Molecular Biology Baylor College of Medicine, Texas Medical Center Houston.
1976-1978: Research Assistant Scientist Immunology Dept Rush Presbyterian St. Luke's Hospital, Rush Presbyterian St. Luke Medical Center, Chicago IL.

BLOCK 2: RESEARCH AND DEVELOPMENT

2016-Present: Consultant/Visiting Biomedical Research Faculty Mechanical & Energy Engineering University of North Texas – Denton TX.
1988-1988: Manager, Quality Control/Product Development and Scientist Genomics. BIOS Corporation, Hamden, CT.

1983-1985: Manager. Immunology/New Products Research and Development and Research Associate Scientist Kallestad Corporation, Austin, TX.
 1982-1983: Microbiologist III/ Immuno-Assay Development and Implementation Texas Animal Health Commission (new position). Austin, TX.

BLOCK 3: CONSULTING

2014 - Present Consultant
 * Manos Unidas, Dallas, TX.
 *HeimBiotek- Korea and Terra Instrument TX molecular diagnostic and research solutions
 *Patient Safety Consortium Simulation Research: UNT HSC – School Public Health, College of Pharmacy, Geriatric Facility, UNT College of Business- Logistics, UNT College Education – Office Research Consulting, Johns Hopkins – Breast Center, Wal-Mart Wellness and Health.
 *Baylor Scott and White Charles Sammons Cancer Center (CSCC) Dallas, TX:
 *University of North Texas Health Science Center Fort Worth, TX: Research Division, Fort Worth, TX.

BLOCK 4: EXECUTIVE and SENIOR ADMINISTRATION – Academia and Clinical

2014- 2015: Special Advisor Vice President Research University North Texas Health Science Center, Fort Worth, TX.
 2011- 2014: Assistant Vice President, UNT Research Development (promotion)/2013 Adjunct Research Assistant Professor Biology; University of North Texas, Denton TX.
 2008-2011: Senior Director Research, Director Science, Technology, Engineering and Math (inaugural position) University of North Texas, Denton TX.
 2005-2008: Director, Oncology Research Center (inaugural position), The John Theurer Cancer Center and Program Manager Sanzari Children's Pediatric NCI-Community Clinical Oncology Program, Hackensack University Medical Center 775 bed hospital, Hackensack, NJ.

STUDENTS MENTORED (released on request)

PARTNERSHIPS LIST (released on request)

CREATIVE and SCHOLARLY WORKS

Grants

Pending Grants

2017	\$275K, NCI R21 Translational/Clinical Exploratory Research "Characterization of a Novel Class of Thermal Markers in CTCL Dept Mechanical and Energy Engineering Tae-Youl Choi, Ph.D. [PI] and Denise Perry Simmons, Ph.D. [Co=PI]
2017	\$200K, CPRIT High Risk/High Impact "A Novel Protocol for Photothermal Treatment of Cutaneous T-cell Lymphoma" UNT Dept. Chemistry Mohammad Omary,, Ph.D. [PI], Denise Perry Simmons, Ph.D..[I]
2017	\$200K, CPRIT High Risk/High Impact: " Thermal characterization at cellular level in gold nanoparticles: Photothermal Therapy approaches to optimal treatment in cervical cancer"., UNT College Engineering, Dept. Mechanical and Energy, Tae-Youl Choi , Ph.D.[PI], Denise Perry Simmons, Ph.D. [I]
2017	\$750K, AHRQ: Advances in Patient Safety through Simulation Research, Francis Rosinia, M.D. [PI], Harvey Brenner, Ph.D., Wesley Randall, Ph.D., Denise Perry Simmons, Ph.D.

Active or Completed

2015	\$40Thousand Baylor Charles Sammons Cancer Center and UNT: Mohammad Omary, Ph.D., Alan Miller, M.D. and Denise Perry Simmons, Ph.D., Nano-particleTreatments for Cutaneous TCL July 2014- July 2015
2009	\$30Thousand American Society of Clinical Oncology (ASCO): Denise Perry Simmons, Ph.D. "Information Technology and Clinical Research", July 2008-June 2009 PI/PD
2009	\$750Thousand NIH-Clinical Community Oncology Program (CCOP): Richard Rosenbluth, M.D. and Denise Perry Simmons, Ph.D. 2008-2009. Co-Author /PD

- 2008* \$1.3 Million State of New Jersey \$9.5M large institutional: Andrew Pecora, M.D., Andre Goy, M.D., Denise Perry Simmons, Ph.D. and Michele Donato, M.D. Ovarian Clinical Cancer Research, August 2007 – July 2008. Author and Co-PI
- 2008 \$1.2 Million State of New Jersey: Andre Goy, M.D. and Denise Perry Simmons, Ph.D. Bio- specimen and Genomics Tumor Bank – infrastructure and clinical and research protocol development, August 2007 – July 2008. Author and Program Director
- 2008 \$750Thousand NIH-Clinical Community Oncology Program (CCOP): Richard Rosenbluth, M.D. and Denise Perry Simmons, Ph.D. 2007-2008. Co-Author/PD

Authored Patents

- 2006 US 20060270605: Compositions and methods for inhibiting cell growth and modulating gene expression. Government of the USA represented by Secretary Department of HealthHuman Services November 2006 (NCI)
- 2004 WO 2005/065666: International Patent Application 60/531,876 Government of the United States of America Represented By The Secretary Department of Health and Human Services July 2005: "Method and composition for inhibition of metastatic melanoma: Use of a pkc-delta inhibitor. Sole inventor, Dec 2004(NCI)
- 2004 U.S. No. 60/613,256 "Lateran, related compounds and methods of use" Sole inventor, Sept 2004(NCI)
- 2003 US 20050164943 Tumor suppressor gene polypeptides and related nucleic acids, host cells, compositions, and methods of use in inhibition of cell growth, modulation of gene expression, and enhancement of immune-response inducing effect of a vaccine. Department of Health and Human Services July 2005. WO 2003/092593 U.S. No. 60/377,827(10/513,114). Government of the United States of America November 2003: Sole Inventor (NCI)
- 2002 International Patent Application No. PCT/US 3/13287: Government of the United States of America "Tumor Suppressor Gene Polypeptides and Related nucleic acids, host cells, compositions, and methods of use in inhibition of cell growth, modulation of gene expression, and enhancement of immune-response inducing effect of a vaccine" May 2002. Sole Inventor (NCI).
- 2002 U.S. No. 60/422,821 "Methods of Assessing Mammal's Risk of Developing Cutaneous Melanoma or Metastatic Melanoma" October 2002. Primary Inventor (NCI)
- 2002 U.S. No. 60/422,733 "Method of Distinguishing Epithelioid Melanoma from Fibroblastoid Melanoma" October 2002. Sole Inventor (NCI)
- 1985 Licensed to DuPont"Diagnostic Assay Panel Upper Respiratory Viral Diseases" Nov. 1985 Kallestad

Publications (refereed)

Journals

- 2016 Park, Byoung Kyoo, Yunho Woo, Dayeong Jeong, Jaesung Park, Tae-Youl Choi, Denise Perry Simmons, Jeonghong Ha and Dongsik Kim.2016. Thermal conductivity of biological cells at cellular level and correlation with disease state. Journal of Applied Physics.119: 224701
- 2006 Simmons Denise Perry, Megan L. Peach, Jonathan R. Friedman, Michael M.B. Green, Marc C. Nicklaus, and Luigi M. De Luca. 2006. Evidence that sequence homologous region in LRAT-like proteins possesses anti-proliferative activity and DNA binding properties: translational implications and mechanism of action. Carcinogenesis. 27(4):693-707
- 2003 Simmons, D.P., F. Andreola, and L.M. De Luca. Lecithin retinol acyltransferase (LRAT) snps in human cutaneous melanoma. Human Genome Variation Database: Feb 2003
- 2002 Simmons, D.P., F. Andreola, and L. M. De Luca. 2002. Human melanoma of fibroblast and epithelial morphology differ widely in their ability to synthesize retinyl esters. Carcinogenesis. 23: 1821-183
- 2001 Zhou, Q., W. Duan, D. Simmons, Y. Shayo, M. Raymond, R. Dorr, and L. Hurley. 2001. Design and synthesis of a novel DNA-DNA interstrand adenine-guanine cross-linking agent. J. Am. Chem. Soc. 123: 4865-4866
- 1993 Simmons Perry, D. and B. Haskell. 1993. A new turbidometric assay for quantifying the complement-mediated bactericidal activity of serum. J. Nutr. Immunol. 2: 81-94
- 1993 Hutter, J., D. Perry Simmons, B. Haskell, 1993. Modifications to a method for analysis Clq as protein bound hydroxyproline in euglobin fraction of serum. Clin. Chem. 91: 201
- 1991 Wolinsky, J.S., M. McCarthy, O. Canady, W. Moore, Rui-Jin, C. Shi-Nian, A. Lovett and D. Simmons. 1991. Monoclonal antibody-defined epitope map of expressed Rubella virus protein domains. J. Virol. 65: 3986-3994

Proceedings (select)

- 2005 Simmons, D. P. "PKC isotype switching in human cutaneous melanoma: Studies, translational implications". April 2005. American Association for Cancer Research (AACR). Anaheim, CA
- 2005 Simmons, D. P., M. Peach and S. Roberto "Cellular Retinol Binding Protein-1 is phosphorylated by PKC-delta at S55" April 2005 AACR. Late Breaking Abstracts. Anaheim, CA
- 2005 Simmons, D. P. Rational design of a potent apoptotic agent: Coupling of an anti-proliferative peptide through its cysteine sulfhydryl to protein kinase C delta inhibitor, rottlerin March 2005. Harvard University Medical School. Biomedical Conference Cambridge, MA
- 2004 Simmons, D.P. "Rational design of a potent apoptotic agent: Coupling of an anti-proliferative peptide through its cysteine sulfhydryl to protein kinase C delta inhibitor, rottlerin" November 2004. International Conference on Therapeutic Resistance and Tumor Progression. Philadelphia, PA
- 2002 Simmons, D.P. and L. DeLuca "Tumor Suppressor Gene Peptides of H-TIG3 and Ha-Rev 107 Inhibit Cell Proliferation and Behave as Biological Response Modifiers in Cultured Human Melanoma Cells" August 2002 Cold Spring Harbor Meetings: Cancer Genetics and Tumor Suppressor Genes. Cold Spring Harbor, New York.
- 2000 Simmons, D.P. and L.H. Hurley. "Solution structure interaction of the anti-tumor compound Et 743 with TGC emphasizes importance of 3'GC hydrogen bonding in stable adduct formation" 2000 AACR, San Diego, CA
- 1996 Simmons, D.P. and S.M. Fischer. "Basal epidermal keratinocytes respond to IL-1 and IL-1 receptor antagonist via functional receptors" 1996 AACR Washington, D.C.
- 1994 Simmons, D.P. and E. Richie 1994, "Genetic imprinting may play a role in N-methyl-N-nitrosourea-induced lymphomagenesis", AACR. San Francisco, CA

Other (select)

- 1982-1983 Designed, then developed with team of scientists, and Implemented State of Texas Animal Health Commission ELISA Test for Brucellosis – transitioned from Card to ELISA as Immunologist for Texas Animal Health Commission, offered Interim Director position

INVITED TALKS, PANELS, LECTURES (select)

- 2017 NIH-NCI Graduate Student Recruiting Program Bethesda, MD May 3-4
- 2015 Texas College HBCU STEM Initiative "The 'AAA' Steps to Success" Tyler, TX Apr 2015
- 2014 FDA: 2014 AACR "University No Smoking Policies – How Can Schools of Journalism Engage?" San Diego, CA, Apr 2014.
- 2014 Cancer Prevention Research Institute of Texas: The state of the \$3 billion dollar CPRIT investment senior level state-wide stakeholder discussions – panels- presentations and stakeholders written recommendations to the State 2013-2014 hosts Cancer Alliance of Texas, Baylor Health Care, Dallas, TX
- 2014 Texas Promotores and Autism- Guest Speaker – "Autism in the Hispanic Community: Clinical Research Participation" UNT Kristen Farmer Autism Ctr, Denton TX, Apr
- 2014 FEMA and Texas Promotores Emergency Management Training Guest Speaker "Researcher collaborations and funding opportunities in Emergency Management" UNT_Denton, TX, Mar
- 2013 Texas Promotores Annual Meeting_ Guest Speaker_ "Engaging Academia – How can WE Help?" Dallas, TX, Oct
- 2013 Future of Academic Publishing: 4th annual Open Access Symposium: Invited Panel Speaker and Strategic Planning – Mission Statement and Goals, Dallas TX, May
- 2013 National Conference Education, International Conference Parent Education and Parenting: Invited Speaker, "Preserving the Legacy" Denton, TX, Mar
- 2013 Global Research Funding Forum: Invited speaker and host assignment Europe, France, Norway, Scientific, Research and Education Consulates, Denton, TX, Feb
- 2012 UNT Classes Biology, Chemistry: Public Health in Education, Denton, TX 2011- 2012
- 2011 UNT Graduate Student Professional Development Series, Denton, TX (2014, 2013, 2012, 2011)
- 2010 UNT Graduate Black Students Association. Keynote May 7
- 2009 UNT Ronald E. McNair Scholars Summer Research Course: "The Path to Research Tools for Grant Writing, Networking, Vita Building" 3-hour lecture, Jul 2013, 2010, 2009

2009	UNT "Woman to Woman-Success Strategies for Graduate School"_ panel moderator_ 2 hour presentation, Sept 30
2009	National Ronald E. McNair Scholars and Mentors Program Welcome talk and Introductory Remarks, Sept 11
2009	Dallas Chamber and Dallas-Fort Worth Technology Business Council-Dallas, Texas, Panel introductory remarks: "Texas on Top of Cancer Research" Cancer Prevention Research Institute Texas (CPRIT), Aug 26
2009	Health Science Center - UNT, Fort Worth, Texas. Life Sciences Regional Alliance,.15 minute talk on Cancer Research and role of collaboration between industry and science, Mar 19
2008	Brown University. Providence, Rhode Island. "Physics, Biophysics, and Medicine: What does this science look like in the future of translational research and how does one prepare?" One hour talk graduate students and junior faculty, Mar 5
2006	National Cancer Institute, Department of Genetics and Cancer Research, Bethesda, MD. "Rational design new generation of CC-1065 analogues based on an irreversible biochemical mechanism", 15-minute Oct 2006
2006	Newsweek Magazine, Washington, D.C. Coalition of Cancer Research Cooperatives. Panel discussions on cancer research, funding initiatives, clinical trials and insurance, Oct
2006	Harvard University Medical School. Biomedical Conference. Cambridge, MA,. "Rational design of a potent apoptotic agent: Coupling of an anti-proliferative peptide through its cysteine sulfhydryl to protein kinase C delta inhibitor, rottlerin", talk, Mar
2004	Friends of Cancer Research. Washington, D.C., Capitol. "Bench to Bedside" panel discussions to educate decision makers, the media and public about cancer research initiatives and agenda, Jul
2003	Molecular Targets Faculty, National Cancer Institute, Bethesda, MD "Mutated catalytic cysteine in lecithin retinol acyltransferase (LRAT) generates tumor suppressor activity: peptides of the homologous regions of LRAT and tumor suppressor gene peptides, H-TIG3 and H-REV107, demonstrate anti-proliferative, anti-tumor and cytostatic effects against cutaneous melanoma"; one-hour talk
2003	Lucien Symposium. St. Edwards University, Austin, TX,"Cancer Progress Report and the Nation's Investment in Cancer Research"; one-hour talk
1999	University of Texas Open House, College of Pharmacy Department of Medicinal Chemistry. Austin, TX, "Telomerase, Aging and Drug Design"; one-hour talk

COMMUNITY and PROFESSIONAL ACTIVITIES

Professional Appointments (select)

Hackensack University Medical Center Committees

- *Center of Excellence
- *Chair Cancer Center IRB
- *Comprehensive Cancer Center Initiative
- *Finance
- *Operations
- *Quality Assurance
- *Pharmacy, Nursing and Patient Safety –Joint Commission
- *Scientific Development (Co-chair)
- *Pediatric Intensive Care Unit
- *Cancer Center NJ Primary Care Physician Oncology Network
- *Special Committee Consortium Big Pharma Big Pharma Legal Counsel, Cancer Centers Multiple Myeloma Research Consortium as Model: Dana Farber, Moffitt, Roswell Park, Mayo, Ohio, Washington, Michigan, University Chicago, City of Hope, Emory, St. Vincent, UCSF – standardizing legal ease clinical trial contracts

National Institutes of Health

- *Space Committee NCI Representative: new open space labs concept
- *HHS Translational Research Initiative Ph.D. and M.D. Collaborative –NCI representative

University of North Texas

- *Libraries Data Management and Open Access Initiative
- *Texas State Health Plan
- *Representative to North Texas Regional Metroplex Cancer Coalition
- *Representative Cancer Alliance of Texas

- *International Graduate Student Global Research Forum Host to England, Germany and Sweden Ambassadors of Education
- *Representative to Dallas Regional Chamber- North Texas Regional Metroplex Life Science Council
- *Representative to Dallas Regional Chamber- Corporate Business Recruitment Council

Advisory Councils (external)

NATIONAL

- *Patient Advocacy Healthcare Disparities ThinkTank Robert Wood Johnson

STATE

- *State of Texas Health Plan, Cardiovascular Disease & Stroke, Austin, TX
- *Board Member IMPACT NJ: New Jersey Commission on Cancer Research Trenton, NJ

COMMUNITY

- *Technology Business Council – Health Care Recruitment Committee. Dallas Regional Chamber
- *Cook Children's Research Development Council, Cook Children's Medical Center, Fort Worth, TX
- *DFW -Metroplex Life Science Council Task Force- Coalition on Cancer Research, Dallas, TX

PRIVATE-NON-PROFIT

- *EDICT Baylor College Medicine: Eliminating Disparities Clinical Trials, Houston, TX
- *Scientific Advisor Life Lover Foundation leukemia Boca Raton, FL
- *Scientific Advisor: SOPHIC Systems Scientific ,Medical Research Software, NCI CaBig, VA

Invited Reviewer

- *2016-present: Comments Inorganic Chemistry
- *2011, 2012 NASA Medical Research Grant Awards Cook Children's Fort Worth, TX
- *2011 Leonardo da Vinci Award_Invited Reviewer, Milan Italy
- *2009 NSF Panel section MRI Instrumentation
- *2009 NSF Panel Large Proposals: Academic Research Infrastructure
- *2007 - present: Bioorganic & Medicinal Chemistry Letters; Elsevier
- *2004 - present: Cancer Genetics & Cytogenetics; Cytogenetic and Genome Research

Society, Professional Memberships

- *American Association for Cancer Research (AACR)
- *AACR-Immunology in Cancer Research Working Group
- *AACR- Minorities in Cancer Research Working Group
- *American Association Clinical Oncologists (ASCO)
- *American Chemical Society (ACS)
- *Cancer Alliance of Texas (CAT) *CAT-Early Detection and Prevention Working Group, Affordable Care Act Committee, Smoking Cessation Texas Private and State University Policies
- *Kappa Omicron Nu Professional Honor Society
- *KSEA Korean Scientists and Engineers (US-Korean Collaborations)

Community Engagement

- *Expanding Your Horizons (EYH): North Texas metro-plex organization for fostering STEM education young females, Denton, TX
- *Harvard Law School Alumnae Parent's Organization – NY, NY
- *University of Southern California Ambassador Eastern Region, MD
- *State Science Fair Judge: CT, IL, TX
- *Westwood High Student Events Fundraising Chair – PTO, Austin, TX
- *Stark Elementary School Reading List Committee PTO, Stamford, CT
- *Cultural Arts Committee Chair, Round Rock ISD, TX
- *School Board Liaison, Fort Bend ISD, TX
- *Ancona Montessori, Events Chair, Chicago, IL
- *President Town and Country Montessori PTO, Austin, TX
- *Governor Richards Committee on Higher Education, Austin, TX